s095029
mAbexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 15, 2021 (NCT05162755)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
inhibitor - NKG2A
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06116136 | Phase 1/Phase 2 (Phase 2) | Apr 15, 2024 | Merck, Servier |
| NCT06162572 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2024 | Regeneron, Servier |
| NCT05162755 | Phase 1 | Oct 15, 2021 | Servier, The START Center for Cancer Care |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Servier | For profit | 3 | 3 | 2 | 2021 |
| Merck | For profit | 1 | 0 | 1 | 2024 |
| Regeneron | For profit | 1 | 0 | 1 | 2024 |
| The START Center for Cancer Care | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1